MA34939B1 - Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation - Google Patents

Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Info

Publication number
MA34939B1
MA34939B1 MA35350A MA35350A MA34939B1 MA 34939 B1 MA34939 B1 MA 34939B1 MA 35350 A MA35350 A MA 35350A MA 35350 A MA35350 A MA 35350A MA 34939 B1 MA34939 B1 MA 34939B1
Authority
MA
Morocco
Prior art keywords
diseases
prevention
treatment
heterocyclylbenzyl
pyrazoles
Prior art date
Application number
MA35350A
Other languages
English (en)
Inventor
Michael Härter
Hartmut Beck
Susanne Greschat-Schade
Peter Ellinghaus
Kerstin Unterschemman
Joachim Schuhmacher
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44063276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34939(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34939B1 publication Critical patent/MA34939B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux dérivés de 1-[3-(hétérocyclyl)benzyl]-1H-pyrazole, leur procédé de fabrication, leur utilisation pour le traitement et/ou la prévention de maladies ainsi que leur utilisation pour la fabrication de médicaments pour le traitement et/ou la prévention de maladies, en particulier pour le traitement et/ou la prévention de maladies hyperprolifératives et angiogéniques telles que ces maladies qui sont provoquées par une adaptation métabolique à des états hypoxiques. De tels traitements peuvent avoir lieu en tant que monothérapie ou aussi en combinaison avec d'autres médicaments ou d'autres mesures thérapeutiques.
MA35350A 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation MA34939B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004855 2010-05-08
PCT/EP2011/057021 WO2011141326A1 (fr) 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Publications (1)

Publication Number Publication Date
MA34939B1 true MA34939B1 (fr) 2014-03-01

Family

ID=44063276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35350A MA34939B1 (fr) 2010-05-08 2011-05-03 Hétérocyclylbenzyle-pyrazoles substituées et leur utilisation

Country Status (26)

Country Link
US (2) US20130172311A1 (fr)
EP (1) EP2569312B1 (fr)
JP (1) JP5727002B2 (fr)
KR (1) KR20130108997A (fr)
CN (1) CN103003269B (fr)
AR (1) AR081368A1 (fr)
AU (1) AU2011252223A1 (fr)
BR (1) BR112012028651A2 (fr)
CA (1) CA2798375A1 (fr)
CO (1) CO6640218A2 (fr)
CR (1) CR20120570A (fr)
CU (1) CU20120157A7 (fr)
DO (1) DOP2012000284A (fr)
EA (1) EA201291167A1 (fr)
EC (1) ECSP12012288A (fr)
ES (1) ES2462522T3 (fr)
IL (1) IL222851A0 (fr)
MA (1) MA34939B1 (fr)
MX (1) MX2012012960A (fr)
PE (1) PE20130228A1 (fr)
PH (1) PH12012502202A1 (fr)
SG (1) SG185459A1 (fr)
TN (1) TN2012000531A1 (fr)
TW (1) TW201200510A (fr)
UY (1) UY33369A (fr)
WO (1) WO2011141326A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688247A (zh) * 2007-05-01 2010-03-31 希尔氏宠物营养品公司 猫科动物骨关节炎的诊断方法和组合物
WO2008141731A2 (fr) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Dérivés pyrazoles à substitution hétéroaryle utiles pour le traitement de troubles hyperprolifératifs et de maladies associées à l'angiogenèse
EA201291167A1 (ru) * 2010-05-08 2013-05-30 Байер Интеллектуэль Проперти Гмбх Замещенные гетероциклилбензилпиразолы и их применение
UA114915C2 (uk) 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
WO2014031928A2 (fr) * 2012-08-24 2014-02-27 Philip Jones Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
EP2888253A4 (fr) 2012-08-24 2016-01-06 Univ Texas Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
DK2888255T3 (en) 2012-08-24 2018-10-29 Univ Texas HETOCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
WO2015130790A2 (fr) 2014-02-25 2015-09-03 Board Of Regents, University Of Texas System Sels de modulateurs hétérocycliques de l'activité de hif pour le traitement de maladies
US10191597B2 (en) 2015-06-30 2019-01-29 Synaptics Incorporated Modulating a reference voltage to preform capacitive sensing
WO2018131657A1 (fr) * 2017-01-13 2018-07-19 日産化学工業株式会社 Procédé de production d'un précurseur de composé diamine aromatique
WO2021216530A1 (fr) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Traitement d'infections virales, d'une lésion d'organe et d'états apparentés à l'aide d'un inhibiteur de hif prolyl hydroxylase ou d'un stabilisateur hif-alpha
CN115944626B (zh) * 2022-12-08 2024-04-19 桂林医学院附属医院 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用
AU2024371427A1 (en) * 2023-10-30 2026-06-04 Pretzel Therapeutics, Inc. Compositions and inhibitors of polrmt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610726B2 (en) * 2001-06-29 2003-08-26 North Shore-Long Island Jewish Research Institute Compositions and agents for modulating cellular proliferation and angiogenesis
EP1613614A2 (fr) 2003-04-03 2006-01-11 Merck & Co., Inc. Modulateurs au pyrazole a substitution diaryle du recepteur-5 de glutamate metabotropique
CN1842332A (zh) * 2003-06-30 2006-10-04 Hif生物公司 化合物、组合物及方法
JP4499721B2 (ja) 2003-06-30 2010-07-07 ヒフ バイオ，インク． 化合物、組成物および方法
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
WO2007065010A2 (fr) 2005-12-02 2007-06-07 Hif Bio, Inc. Composes anti-angiogenese
WO2008141731A2 (fr) * 2007-05-18 2008-11-27 Bayer Healthcare Ag Dérivés pyrazoles à substitution hétéroaryle utiles pour le traitement de troubles hyperprolifératifs et de maladies associées à l'angiogenèse
CA2743424A1 (fr) * 2008-11-14 2010-05-20 Michael Haerter Composes heteroaromatiques pour une utilisation comme inhibiteurs de hif
DE102008057344A1 (de) * 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
AU2009316019A1 (en) * 2008-11-14 2010-05-20 Bayer Intellectual Property Gmbh Heterocyclically substituted aryl compounds as HIF inhibitors
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
EA201291167A1 (ru) * 2010-05-08 2013-05-30 Байер Интеллектуэль Проперти Гмбх Замещенные гетероциклилбензилпиразолы и их применение

Also Published As

Publication number Publication date
CN103003269B (zh) 2015-11-25
WO2011141326A1 (fr) 2011-11-17
KR20130108997A (ko) 2013-10-07
TW201200510A (en) 2012-01-01
EP2569312B1 (fr) 2014-03-26
UY33369A (es) 2011-12-01
US20120028950A1 (en) 2012-02-02
CR20120570A (es) 2013-04-22
EP2569312A1 (fr) 2013-03-20
CN103003269A (zh) 2013-03-27
US8470811B2 (en) 2013-06-25
PE20130228A1 (es) 2013-03-15
US20130172311A1 (en) 2013-07-04
AU2011252223A1 (en) 2012-12-06
IL222851A0 (en) 2012-12-31
ECSP12012288A (es) 2012-12-28
CA2798375A1 (fr) 2011-11-17
TN2012000531A1 (en) 2014-04-01
CU20120157A7 (es) 2013-03-27
JP5727002B2 (ja) 2015-06-03
EA201291167A1 (ru) 2013-05-30
JP2013526497A (ja) 2013-06-24
MX2012012960A (es) 2012-12-17
DOP2012000284A (es) 2013-03-31
AR081368A1 (es) 2012-08-29
ES2462522T3 (es) 2014-05-23
BR112012028651A2 (pt) 2016-08-09
PH12012502202A1 (en) 2013-02-04
CO6640218A2 (es) 2013-03-22
SG185459A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
EA201291167A1 (ru) Замещенные гетероциклилбензилпиразолы и их применение
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
MA47079A (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MY164376A (en) Phosphospecific antibodies recognizing tau
MA33538B1 (fr) Nouveaux antagonistes pyrimidine et triazine de l'hepcidine
MA32784B1 (fr) Composes aryles substitues par heterocycle comme inhibiteurs de hif
MY171300A (en) Pharmaceutical composition
MA33279B1 (fr) Compositions et procédés pour l'augmentation de la croissance des muscles
MA33123B1 (fr) 2-acetamido-5-aryl-1,2,4-triazolones substitues et leur utilisation
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201270480A1 (ru) Новые соединения
WO2009082038A3 (fr) Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA34517B1 (fr) Promédicaments comprenant un conjugué exendine-lieur
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA35285B1 (fr) Indazoles
WO2011045415A3 (fr) Nouveaux agents d'imagerie et leur utilisation pour le diagnostic in vivo de maladies neurodégénératives, notamment la maladie d'alzheimer et les maladies dérivées
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
DOP2010000232A (es) Derivados de indazol
BR112012019902A2 (pt) "método e compostos para o crescimento muscular"